Evaluation of two sexual-stage antigens as bivalent transmission-blocking vaccines in rodent malaria
Transmission-blocking vaccine (TBV) is a promising strategy for malaria elimination. It is hypothesized that mixing or fusing two antigens targeting different stages of sexual development may provide higher transmission-blocking activity than these antigens used individually. A chimeric protein comp...
Saved in:
| Published in | Parasites & vectors Vol. 14; no. 1; p. 241 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
07.05.2021
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Transmission-blocking vaccine (TBV) is a promising strategy for malaria elimination. It is hypothesized that mixing or fusing two antigens targeting different stages of sexual development may provide higher transmission-blocking activity than these antigens used individually.
A chimeric protein composed of fragments of Pbg37 and PSOP25 was designed and expressed the recombinant protein in Escherichia coli Rosetta-gami B (DE3). After immunizing mice with individual recombinant proteins Pbg37 and PSOP25, mixed proteins (Pbg37+PSOP25), or the fusion protein (Pbg37-PSOP25), the antibody titers of individual sera were analyzed by ELISA. IFA and Western blot were performed to test the reactivity of the antisera with the native proteins in the parasite. The transmission-blocking activity of the different immunization schemes was assessed using in vitro and in vivo assays.
When Pbg37 and PSOP25 were co-administered in a mixture or as a fusion protein, they elicited similar antibody responses in mice as single antigens without causing immunological interference with each other. Antibodies against the mixed or fused antigens recognized the target proteins in the gametocyte, gamete, zygote, and ookinete stages. The mixed proteins or the fusion protein induced antibodies with significantly stronger transmission-reducing activities in vitro and in vivo than individual antigens.
There was no immunological interference between Pbg37 and PSOP25. The bivalent vaccines, which expand the portion of the sexual development during which the transmission-blocking antibodies act, produced significantly stronger transmission-reducing activities than single antigens. Altogether, these data provide the theoretical basis for the development of combination TBVs targeting different sexual stages. |
|---|---|
| AbstractList | Transmission-blocking vaccine (TBV) is a promising strategy for malaria elimination. It is hypothesized that mixing or fusing two antigens targeting different stages of sexual development may provide higher transmission-blocking activity than these antigens used individually.BACKGROUNDTransmission-blocking vaccine (TBV) is a promising strategy for malaria elimination. It is hypothesized that mixing or fusing two antigens targeting different stages of sexual development may provide higher transmission-blocking activity than these antigens used individually.A chimeric protein composed of fragments of Pbg37 and PSOP25 was designed and expressed the recombinant protein in Escherichia coli Rosetta-gami B (DE3). After immunizing mice with individual recombinant proteins Pbg37 and PSOP25, mixed proteins (Pbg37+PSOP25), or the fusion protein (Pbg37-PSOP25), the antibody titers of individual sera were analyzed by ELISA. IFA and Western blot were performed to test the reactivity of the antisera with the native proteins in the parasite. The transmission-blocking activity of the different immunization schemes was assessed using in vitro and in vivo assays.METHODSA chimeric protein composed of fragments of Pbg37 and PSOP25 was designed and expressed the recombinant protein in Escherichia coli Rosetta-gami B (DE3). After immunizing mice with individual recombinant proteins Pbg37 and PSOP25, mixed proteins (Pbg37+PSOP25), or the fusion protein (Pbg37-PSOP25), the antibody titers of individual sera were analyzed by ELISA. IFA and Western blot were performed to test the reactivity of the antisera with the native proteins in the parasite. The transmission-blocking activity of the different immunization schemes was assessed using in vitro and in vivo assays.When Pbg37 and PSOP25 were co-administered in a mixture or as a fusion protein, they elicited similar antibody responses in mice as single antigens without causing immunological interference with each other. Antibodies against the mixed or fused antigens recognized the target proteins in the gametocyte, gamete, zygote, and ookinete stages. The mixed proteins or the fusion protein induced antibodies with significantly stronger transmission-reducing activities in vitro and in vivo than individual antigens.RESULTSWhen Pbg37 and PSOP25 were co-administered in a mixture or as a fusion protein, they elicited similar antibody responses in mice as single antigens without causing immunological interference with each other. Antibodies against the mixed or fused antigens recognized the target proteins in the gametocyte, gamete, zygote, and ookinete stages. The mixed proteins or the fusion protein induced antibodies with significantly stronger transmission-reducing activities in vitro and in vivo than individual antigens.There was no immunological interference between Pbg37 and PSOP25. The bivalent vaccines, which expand the portion of the sexual development during which the transmission-blocking antibodies act, produced significantly stronger transmission-reducing activities than single antigens. Altogether, these data provide the theoretical basis for the development of combination TBVs targeting different sexual stages.CONCLUSIONSThere was no immunological interference between Pbg37 and PSOP25. The bivalent vaccines, which expand the portion of the sexual development during which the transmission-blocking antibodies act, produced significantly stronger transmission-reducing activities than single antigens. Altogether, these data provide the theoretical basis for the development of combination TBVs targeting different sexual stages. Background Transmission-blocking vaccine (TBV) is a promising strategy for malaria elimination. It is hypothesized that mixing or fusing two antigens targeting different stages of sexual development may provide higher transmission-blocking activity than these antigens used individually. Methods A chimeric protein composed of fragments of Pbg37 and PSOP25 was designed and expressed the recombinant protein in Escherichia coli Rosetta-gami B (DE3). After immunizing mice with individual recombinant proteins Pbg37 and PSOP25, mixed proteins (Pbg37+PSOP25), or the fusion protein (Pbg37-PSOP25), the antibody titers of individual sera were analyzed by ELISA. IFA and Western blot were performed to test the reactivity of the antisera with the native proteins in the parasite. The transmission-blocking activity of the different immunization schemes was assessed using in vitro and in vivo assays. Results When Pbg37 and PSOP25 were co-administered in a mixture or as a fusion protein, they elicited similar antibody responses in mice as single antigens without causing immunological interference with each other. Antibodies against the mixed or fused antigens recognized the target proteins in the gametocyte, gamete, zygote, and ookinete stages. The mixed proteins or the fusion protein induced antibodies with significantly stronger transmission-reducing activities in vitro and in vivo than individual antigens. Conclusions There was no immunological interference between Pbg37 and PSOP25. The bivalent vaccines, which expand the portion of the sexual development during which the transmission-blocking antibodies act, produced significantly stronger transmission-reducing activities than single antigens. Altogether, these data provide the theoretical basis for the development of combination TBVs targeting different sexual stages. Graphic Abstract Background Transmission-blocking vaccine (TBV) is a promising strategy for malaria elimination. It is hypothesized that mixing or fusing two antigens targeting different stages of sexual development may provide higher transmission-blocking activity than these antigens used individually. Methods A chimeric protein composed of fragments of Pbg37 and PSOP25 was designed and expressed the recombinant protein in Escherichia coli Rosetta-gami B (DE3). After immunizing mice with individual recombinant proteins Pbg37 and PSOP25, mixed proteins (Pbg37+PSOP25), or the fusion protein (Pbg37-PSOP25), the antibody titers of individual sera were analyzed by ELISA. IFA and Western blot were performed to test the reactivity of the antisera with the native proteins in the parasite. The transmission-blocking activity of the different immunization schemes was assessed using in vitro and in vivo assays. Results When Pbg37 and PSOP25 were co-administered in a mixture or as a fusion protein, they elicited similar antibody responses in mice as single antigens without causing immunological interference with each other. Antibodies against the mixed or fused antigens recognized the target proteins in the gametocyte, gamete, zygote, and ookinete stages. The mixed proteins or the fusion protein induced antibodies with significantly stronger transmission-reducing activities in vitro and in vivo than individual antigens. Conclusions There was no immunological interference between Pbg37 and PSOP25. The bivalent vaccines, which expand the portion of the sexual development during which the transmission-blocking antibodies act, produced significantly stronger transmission-reducing activities than single antigens. Altogether, these data provide the theoretical basis for the development of combination TBVs targeting different sexual stages. Graphic Keywords: Transmission-blocking vaccine, Dual-antigen, Immunological interference, Transmission-blocking activity BACKGROUND: Transmission-blocking vaccine (TBV) is a promising strategy for malaria elimination. It is hypothesized that mixing or fusing two antigens targeting different stages of sexual development may provide higher transmission-blocking activity than these antigens used individually. METHODS: A chimeric protein composed of fragments of Pbg37 and PSOP25 was designed and expressed the recombinant protein in Escherichia coli Rosetta-gami B (DE3). After immunizing mice with individual recombinant proteins Pbg37 and PSOP25, mixed proteins (Pbg37+PSOP25), or the fusion protein (Pbg37-PSOP25), the antibody titers of individual sera were analyzed by ELISA. IFA and Western blot were performed to test the reactivity of the antisera with the native proteins in the parasite. The transmission-blocking activity of the different immunization schemes was assessed using in vitro and in vivo assays. RESULTS: When Pbg37 and PSOP25 were co-administered in a mixture or as a fusion protein, they elicited similar antibody responses in mice as single antigens without causing immunological interference with each other. Antibodies against the mixed or fused antigens recognized the target proteins in the gametocyte, gamete, zygote, and ookinete stages. The mixed proteins or the fusion protein induced antibodies with significantly stronger transmission-reducing activities in vitro and in vivo than individual antigens. CONCLUSIONS: There was no immunological interference between Pbg37 and PSOP25. The bivalent vaccines, which expand the portion of the sexual development during which the transmission-blocking antibodies act, produced significantly stronger transmission-reducing activities than single antigens. Altogether, these data provide the theoretical basis for the development of combination TBVs targeting different sexual stages. Transmission-blocking vaccine (TBV) is a promising strategy for malaria elimination. It is hypothesized that mixing or fusing two antigens targeting different stages of sexual development may provide higher transmission-blocking activity than these antigens used individually. A chimeric protein composed of fragments of Pbg37 and PSOP25 was designed and expressed the recombinant protein in Escherichia coli Rosetta-gami B (DE3). After immunizing mice with individual recombinant proteins Pbg37 and PSOP25, mixed proteins (Pbg37+PSOP25), or the fusion protein (Pbg37-PSOP25), the antibody titers of individual sera were analyzed by ELISA. IFA and Western blot were performed to test the reactivity of the antisera with the native proteins in the parasite. The transmission-blocking activity of the different immunization schemes was assessed using in vitro and in vivo assays. When Pbg37 and PSOP25 were co-administered in a mixture or as a fusion protein, they elicited similar antibody responses in mice as single antigens without causing immunological interference with each other. Antibodies against the mixed or fused antigens recognized the target proteins in the gametocyte, gamete, zygote, and ookinete stages. The mixed proteins or the fusion protein induced antibodies with significantly stronger transmission-reducing activities in vitro and in vivo than individual antigens. There was no immunological interference between Pbg37 and PSOP25. The bivalent vaccines, which expand the portion of the sexual development during which the transmission-blocking antibodies act, produced significantly stronger transmission-reducing activities than single antigens. Altogether, these data provide the theoretical basis for the development of combination TBVs targeting different sexual stages. Abstract Background Transmission-blocking vaccine (TBV) is a promising strategy for malaria elimination. It is hypothesized that mixing or fusing two antigens targeting different stages of sexual development may provide higher transmission-blocking activity than these antigens used individually. Methods A chimeric protein composed of fragments of Pbg37 and PSOP25 was designed and expressed the recombinant protein in Escherichia coli Rosetta-gami B (DE3). After immunizing mice with individual recombinant proteins Pbg37 and PSOP25, mixed proteins (Pbg37+PSOP25), or the fusion protein (Pbg37-PSOP25), the antibody titers of individual sera were analyzed by ELISA. IFA and Western blot were performed to test the reactivity of the antisera with the native proteins in the parasite. The transmission-blocking activity of the different immunization schemes was assessed using in vitro and in vivo assays. Results When Pbg37 and PSOP25 were co-administered in a mixture or as a fusion protein, they elicited similar antibody responses in mice as single antigens without causing immunological interference with each other. Antibodies against the mixed or fused antigens recognized the target proteins in the gametocyte, gamete, zygote, and ookinete stages. The mixed proteins or the fusion protein induced antibodies with significantly stronger transmission-reducing activities in vitro and in vivo than individual antigens. Conclusions There was no immunological interference between Pbg37 and PSOP25. The bivalent vaccines, which expand the portion of the sexual development during which the transmission-blocking antibodies act, produced significantly stronger transmission-reducing activities than single antigens. Altogether, these data provide the theoretical basis for the development of combination TBVs targeting different sexual stages. Graphic Abstract Transmission-blocking vaccine (TBV) is a promising strategy for malaria elimination. It is hypothesized that mixing or fusing two antigens targeting different stages of sexual development may provide higher transmission-blocking activity than these antigens used individually. A chimeric protein composed of fragments of Pbg37 and PSOP25 was designed and expressed the recombinant protein in Escherichia coli Rosetta-gami B (DE3). After immunizing mice with individual recombinant proteins Pbg37 and PSOP25, mixed proteins (Pbg37+PSOP25), or the fusion protein (Pbg37-PSOP25), the antibody titers of individual sera were analyzed by ELISA. IFA and Western blot were performed to test the reactivity of the antisera with the native proteins in the parasite. The transmission-blocking activity of the different immunization schemes was assessed using in vitro and in vivo assays. When Pbg37 and PSOP25 were co-administered in a mixture or as a fusion protein, they elicited similar antibody responses in mice as single antigens without causing immunological interference with each other. Antibodies against the mixed or fused antigens recognized the target proteins in the gametocyte, gamete, zygote, and ookinete stages. The mixed proteins or the fusion protein induced antibodies with significantly stronger transmission-reducing activities in vitro and in vivo than individual antigens. There was no immunological interference between Pbg37 and PSOP25. The bivalent vaccines, which expand the portion of the sexual development during which the transmission-blocking antibodies act, produced significantly stronger transmission-reducing activities than single antigens. Altogether, these data provide the theoretical basis for the development of combination TBVs targeting different sexual stages. |
| ArticleNumber | 241 |
| Audience | Academic |
| Author | Yu, Xinxin Wu, Yudi Liu, Fei Yang, Fan Qiu, Yue Zheng, Wenqi Cui, Liwang Cao, Yaming Jin, Ying |
| Author_xml | – sequence: 1 givenname: Fan surname: Yang fullname: Yang, Fan – sequence: 2 givenname: Fei surname: Liu fullname: Liu, Fei – sequence: 3 givenname: Xinxin surname: Yu fullname: Yu, Xinxin – sequence: 4 givenname: Wenqi surname: Zheng fullname: Zheng, Wenqi – sequence: 5 givenname: Yudi surname: Wu fullname: Wu, Yudi – sequence: 6 givenname: Yue surname: Qiu fullname: Qiu, Yue – sequence: 7 givenname: Ying surname: Jin fullname: Jin, Ying – sequence: 8 givenname: Liwang surname: Cui fullname: Cui, Liwang – sequence: 9 givenname: Yaming surname: Cao fullname: Cao, Yaming |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33962671$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkl2L1DAYhYusuB_6B7yQgjfrRdekadL0RliWVQcWBD-uw9v0Tc3YSdYkHdd_b2ZmXXcWESmhIX3OSXJ6josD5x0WxXNKziiV4nWkjLS0InUeTduwijwqjmjLRcUY4Qf35ofFcYxLQgTpuHhSHDLWiVq09KgYLtcwzZCsd6U3Zfrhy4g3M0xVTDBiCS7ZEV0sIZa9zSy6VKYALq5sjFlV9ZPX36wbyzVobR3G0roy-GEDrmCCYOFp8djAFPHZ7fuk-PL28vPF--rqw7vFxflVpQUjqeIcgfZtQyXte8OhNYyYlmEtARtDoIYOtdSgJYh8f9FhzxgSyjvoGlLX7KRY7HwHD0t1HewKwk_lwartgg-jgpCsnlAZI7kEqmvad40Y-n5AFHpAJhsqWA3Z683O63ruVzjofJ0A057p_hdnv6rRr5WkhAnSZoPTW4Pgv88Yk8qJaZwmcOjnqGrOaUdl28r_QOuGcblzffkAXfo5uJzqhpJdR3Iyf6gx_zBlnfH5iHpjqs6FoA0TQm62PfsLlZ8BV1bnrhmb1_cEr_YEmUl4k0aYY1SLTx_32Rf387sL7nf1MlDvAB18jAHNHUKJ2vRb7fqtcr_Vtt-KZJF8INI2bdubj26nf0l_ASu4_cU |
| CitedBy_id | crossref_primary_10_1186_s13071_023_06071_x crossref_primary_10_3389_fcimb_2025_1529770 crossref_primary_10_1186_s13071_023_06020_8 crossref_primary_10_1016_j_ymthe_2022_04_001 crossref_primary_10_1186_s13071_022_05294_8 |
| Cites_doi | 10.1016/j.celrep.2017.11.024 10.1371/journal.pone.0002636 10.3389/fimmu.2017.01998 10.1111/cmi.13294 10.1016/S0092-8674(01)00199-4 10.1016/j.vaccine.2020.02.011 10.1016/S1473-3099(18)30344-X 10.1128/IAI.66.1.59-64.1998 10.1006/expr.1998.4203 10.1128/CMR.00051-10 10.1038/s41598-018-21801-3 10.1016/j.vaccine.2019.02.021 10.1186/s12936-020-03368-5 10.1016/j.vaccine.2016.06.066 10.1371/journal.pone.0000850 10.1038/mt.2012.223 10.1128/EC.00060-07 10.1371/journal.ppat.1004871 10.1016/j.addr.2012.09.039 10.1038/s41541-018-0084-2 10.1016/j.vaccine.2015.08.073 10.1128/iai.65.3.1109-1113.1997 10.1016/j.vaccine.2016.04.011 10.1146/annurev-micro-090817-062427 10.3390/microorganisms8060916 10.3389/fmicb.2015.00391 10.4049/jimmunol.1201455 10.1016/S0020-7519(02)00190-X 10.1006/expr.2000.4580 10.1016/S1383-5769(02)00037-5 10.1038/415673a 10.3389/fimmu.2019.01256 10.1016/j.pt.2018.07.001 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2021 BioMed Central Ltd. 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s) 2021 |
| Copyright_xml | – notice: COPYRIGHT 2021 BioMed Central Ltd. – notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s) 2021 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM ISR 3V. 7SN 7SS 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR C1K CCPQU DWQXO F1W FYUFA GHDGH H95 K9. L.G M0S M1P M7N PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 7S9 L.6 5PM DOA |
| DOI | 10.1186/s13071-021-04743-0 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Science ProQuest Central (Corporate) Ecology Abstracts Entomology Abstracts (Full archive) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni Edition) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Korea ASFA: Aquatic Sciences and Fisheries Abstracts Health Research Premium Collection Health Research Premium Collection (Alumni) Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources ProQuest Health & Medical Complete (Alumni) Aquatic Science & Fisheries Abstracts (ASFA) Professional Health & Medical Collection (Alumni Edition) Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic AGRICOLA AGRICOLA - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database Aquatic Science & Fisheries Abstracts (ASFA) Professional ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China Environmental Sciences and Pollution Management ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Algology Mycology and Protozoology Abstracts (Microbiology C) Health & Medical Research Collection Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Ecology Abstracts ProQuest Hospital Collection (Alumni) Entomology Abstracts ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ASFA: Aquatic Sciences and Fisheries Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
| DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database AGRICOLA MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Zoology Public Health |
| EISSN | 1756-3305 |
| EndPage | 241 |
| ExternalDocumentID | oai_doaj_org_article_ff858a1c21b946dbbdee6cde3841632a PMC8103607 A661436688 33962671 10_1186_s13071_021_04743_0 |
| Genre | Journal Article |
| GeographicLocations | China Beijing China United States--US |
| GeographicLocations_xml | – name: China – name: Beijing China – name: United States--US |
| GrantInformation_xml | – fundername: NIAID NIH HHS grantid: R01 AI150533 – fundername: NIAID NIH HHS grantid: U19 AI089672 – fundername: ; grantid: 31900674 – fundername: ; grantid: R01AI150533; U19AI089672 |
| GroupedDBID | --- 0R~ 123 29O 2WC 2XV 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABDBF ABUWG ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EBD EBLON EBS ECGQY EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ISR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS UKHRP ~8M CGR CUY CVF ECM EIF NPM PJZUB PPXIY PMFND 3V. 7SN 7SS 7XB 8FK AZQEC C1K DWQXO F1W H95 K9. L.G M7N PKEHL PQEST PQUKI PRINS 7X8 7S9 L.6 5PM PUEGO |
| ID | FETCH-LOGICAL-c630t-55ea1b74181bbf5a7f30f73e28ae4f0a2a9ec8cac8a618669eb33e0159a940223 |
| IEDL.DBID | M48 |
| ISSN | 1756-3305 |
| IngestDate | Wed Aug 27 01:30:30 EDT 2025 Thu Aug 21 14:10:18 EDT 2025 Fri Jul 11 16:50:41 EDT 2025 Tue Aug 05 09:33:14 EDT 2025 Sat Jul 26 02:24:17 EDT 2025 Tue Jun 17 20:55:00 EDT 2025 Tue Jun 10 20:54:18 EDT 2025 Fri Jun 27 05:00:04 EDT 2025 Mon Jul 21 06:04:52 EDT 2025 Tue Jul 01 00:54:08 EDT 2025 Thu Apr 24 23:12:33 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Immunological interference Transmission-blocking activity Transmission-blocking vaccine Dual-antigen |
| Language | English |
| License | Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c630t-55ea1b74181bbf5a7f30f73e28ae4f0a2a9ec8cac8a618669eb33e0159a940223 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://doaj.org/article/ff858a1c21b946dbbdee6cde3841632a |
| PMID | 33962671 |
| PQID | 2528990186 |
| PQPubID | 55241 |
| PageCount | 1 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_ff858a1c21b946dbbdee6cde3841632a pubmedcentral_primary_oai_pubmedcentral_nih_gov_8103607 proquest_miscellaneous_2551918778 proquest_miscellaneous_2524358607 proquest_journals_2528990186 gale_infotracmisc_A661436688 gale_infotracacademiconefile_A661436688 gale_incontextgauss_ISR_A661436688 pubmed_primary_33962671 crossref_primary_10_1186_s13071_021_04743_0 crossref_citationtrail_10_1186_s13071_021_04743_0 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-05-07 |
| PublicationDateYYYYMMDD | 2021-05-07 |
| PublicationDate_xml | – month: 05 year: 2021 text: 2021-05-07 day: 07 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Parasites & vectors |
| PublicationTitleAlternate | Parasit Vectors |
| PublicationYear | 2021 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | RW Sauerwein (4743_CR16) 2015; 33 AK Saxena (4743_CR13) 2007; 6 F Liu (4743_CR30) 2021; 23 R Carter (4743_CR8) 2002; 32 SC Elias (4743_CR34) 2013; 190 G Siciliano (4743_CR5) 2015; 6 M Tachibana (4743_CR11) 2019; 37 MM Gozar (4743_CR20) 2001; 97 X Chen (4743_CR33) 2013; 65 SK Nilsson (4743_CR3) 2015; 11 LH Miller (4743_CR6) 2002; 415 SH Sheehy (4743_CR19) 2012; 20 Y Qiu (4743_CR27) 2020; 38 AL Beetsma (4743_CR29) 1998; 88 T Tsuboi (4743_CR7) 2003; 52 F Angrisano (4743_CR12) 2017; 21 LC Lima (4743_CR28) 2020; 8 WC Huang (4743_CR23) 2020; 19 MB Laurens (4743_CR2) 2018; 72 T Bousema (4743_CR10) 2011; 24 SK Singh (4743_CR24) 2019; 10 W Zheng (4743_CR26) 2016; 34 F Liu (4743_CR25) 2018; 86 M Andreadaki (4743_CR4) 2018; 8 PE Duffy (4743_CR22) 1997; 65 I Sagara (4743_CR15) 2018; 18 MM Gozar (4743_CR21) 1998; 66 A Saul (4743_CR32) 2007; 2 V Menon (4743_CR18) 2017; 8 T Rampling (4743_CR35) 2018; 3 WHO (4743_CR1) 2020 Y Wu (4743_CR14) 2008; 3 MR van Dijk (4743_CR9) 2001; 104 K Miura (4743_CR31) 2016; 34 MJ Delves (4743_CR17) 2018; 34 |
| References_xml | – volume: 21 start-page: 2868 year: 2017 ident: 4743_CR12 publication-title: Cell Rep doi: 10.1016/j.celrep.2017.11.024 – volume: 3 start-page: e2636 year: 2008 ident: 4743_CR14 publication-title: PLoS ONE doi: 10.1371/journal.pone.0002636 – volume: 8 start-page: 1998 year: 2017 ident: 4743_CR18 publication-title: Front Immunol doi: 10.3389/fimmu.2017.01998 – volume: 23 start-page: e13294 year: 2021 ident: 4743_CR30 publication-title: Cell Microbiol doi: 10.1111/cmi.13294 – volume: 104 start-page: 153 year: 2001 ident: 4743_CR9 publication-title: Cell doi: 10.1016/S0092-8674(01)00199-4 – volume: 38 start-page: 2841 year: 2020 ident: 4743_CR27 publication-title: Vaccine doi: 10.1016/j.vaccine.2020.02.011 – volume: 18 start-page: 969 year: 2018 ident: 4743_CR15 publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(18)30344-X – volume: 66 start-page: 59 year: 1998 ident: 4743_CR21 publication-title: Infect Immun doi: 10.1128/IAI.66.1.59-64.1998 – volume: 88 start-page: 69 year: 1998 ident: 4743_CR29 publication-title: Exp Parasitol doi: 10.1006/expr.1998.4203 – volume: 24 start-page: 377 year: 2011 ident: 4743_CR10 publication-title: Clin Microbiol Rev doi: 10.1128/CMR.00051-10 – volume: 8 start-page: 3543 year: 2018 ident: 4743_CR4 publication-title: Sci Rep doi: 10.1038/s41598-018-21801-3 – volume: 37 start-page: 1799 year: 2019 ident: 4743_CR11 publication-title: Vaccine doi: 10.1016/j.vaccine.2019.02.021 – volume: 19 start-page: 309 year: 2020 ident: 4743_CR23 publication-title: Malar J doi: 10.1186/s12936-020-03368-5 – volume: 34 start-page: 4145 year: 2016 ident: 4743_CR31 publication-title: Vaccine doi: 10.1016/j.vaccine.2016.06.066 – volume: 2 start-page: e850 year: 2007 ident: 4743_CR32 publication-title: PLoS ONE doi: 10.1371/journal.pone.0000850 – volume: 20 start-page: 2355 year: 2012 ident: 4743_CR19 publication-title: Mol Ther doi: 10.1038/mt.2012.223 – volume: 6 start-page: 1260 year: 2007 ident: 4743_CR13 publication-title: Eukaryot Cell doi: 10.1128/EC.00060-07 – volume: 11 start-page: e1004871 year: 2015 ident: 4743_CR3 publication-title: PLoS Pathog doi: 10.1371/journal.ppat.1004871 – volume: 65 start-page: 1357 year: 2013 ident: 4743_CR33 publication-title: Adv Drug Deliv Rev doi: 10.1016/j.addr.2012.09.039 – volume: 3 start-page: 49 year: 2018 ident: 4743_CR35 publication-title: NPJ Vaccines doi: 10.1038/s41541-018-0084-2 – volume: 33 start-page: 7476 year: 2015 ident: 4743_CR16 publication-title: Vaccine doi: 10.1016/j.vaccine.2015.08.073 – volume: 65 start-page: 1109 year: 1997 ident: 4743_CR22 publication-title: Infect Immun doi: 10.1128/iai.65.3.1109-1113.1997 – volume: 34 start-page: 2570 year: 2016 ident: 4743_CR26 publication-title: Vaccine doi: 10.1016/j.vaccine.2016.04.011 – volume: 72 start-page: 273 year: 2018 ident: 4743_CR2 publication-title: Annu Rev Microbiol doi: 10.1146/annurev-micro-090817-062427 – volume: 8 start-page: 916 year: 2020 ident: 4743_CR28 publication-title: Microorganisms. doi: 10.3390/microorganisms8060916 – volume: 6 start-page: 391 year: 2015 ident: 4743_CR5 publication-title: Front Microbiol doi: 10.3389/fmicb.2015.00391 – volume: 190 start-page: 1135 year: 2013 ident: 4743_CR34 publication-title: J Immunol doi: 10.4049/jimmunol.1201455 – volume: 32 start-page: 1617 year: 2002 ident: 4743_CR8 publication-title: Int J Parasitol doi: 10.1016/S0020-7519(02)00190-X – volume: 86 start-page: e00785 year: 2018 ident: 4743_CR25 publication-title: Infect Immun – volume-title: World malaria report 2020 year: 2020 ident: 4743_CR1 – volume: 97 start-page: 61 year: 2001 ident: 4743_CR20 publication-title: Exp Parasitol doi: 10.1006/expr.2000.4580 – volume: 52 start-page: 1 year: 2003 ident: 4743_CR7 publication-title: Parasitol Int doi: 10.1016/S1383-5769(02)00037-5 – volume: 415 start-page: 673 year: 2002 ident: 4743_CR6 publication-title: Nature doi: 10.1038/415673a – volume: 10 start-page: 1256 year: 2019 ident: 4743_CR24 publication-title: Front Immunol doi: 10.3389/fimmu.2019.01256 – volume: 34 start-page: 735 year: 2018 ident: 4743_CR17 publication-title: Trends Parasitol doi: 10.1016/j.pt.2018.07.001 |
| SSID | ssj0060956 |
| Score | 2.2970748 |
| Snippet | Transmission-blocking vaccine (TBV) is a promising strategy for malaria elimination. It is hypothesized that mixing or fusing two antigens targeting different... Background Transmission-blocking vaccine (TBV) is a promising strategy for malaria elimination. It is hypothesized that mixing or fusing two antigens targeting... BACKGROUND: Transmission-blocking vaccine (TBV) is a promising strategy for malaria elimination. It is hypothesized that mixing or fusing two antigens... Abstract Background Transmission-blocking vaccine (TBV) is a promising strategy for malaria elimination. It is hypothesized that mixing or fusing two antigens... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 241 |
| SubjectTerms | Animals Antibodies Antibodies, Protozoan - blood Antigens Antisera Blocking antibodies Developmental stages Disease control Disease Models, Animal Disease transmission Drug Evaluation, Preclinical Drug resistance Dual-antigen E coli ELISA Enzyme-linked immunosorbent assay Escherichia coli Female Fusion protein Gametes Gametocytes Human diseases Humans Immunization Immunological interference Immunological research Immunology In vivo methods and tests Insecticides Interference Malaria Malaria - blood Malaria - parasitology Malaria - prevention & control Malaria - transmission Malaria vaccine Malaria Vaccines - administration & dosage Malaria Vaccines - genetics Malaria Vaccines - immunology Mice Mice, Inbred BALB C Mosquitoes ookinetes Parasites Physiological aspects Plasmodium berghei - genetics Plasmodium berghei - growth & development Plasmodium berghei - immunology Prevention Proteins Protozoan Proteins - administration & dosage Protozoan Proteins - genetics Protozoan Proteins - immunology Public health recombinant fusion proteins Recombinants rodents sexual development Sexual stages Sodium Target recognition Transmission-blocking activity Transmission-blocking vaccine Vaccines Vaccines, Combined - administration & dosage Vaccines, Combined - genetics Vaccines, Combined - immunology Vector-borne diseases Western blotting zygote Zygotes |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Ni9UwEA-yIHgRv62uEkXwIGHTps3HcZVdVg8e1IXFS0jSZH2wtmL79N93Ju0rrwjrxUMvzZQ2M9OZ36TTXwh5JYxLUAW0TCYZWO0CZ76OnOkkIBmkJKuYuy0-yrPz-sNFc7G31Rf2hE30wJPijlLSjXZlqEpvatl638YoQxsFfi8TVYZGkPN2xdQUg5FFTe5-kdHyaIBIraBsruCokZSTr9JQZuv_OybvJaV1w-ReBjq9Q27P0JEeT498l9yI3T1y82ufF8bvk_ZkIe6mfaLj754OmU-ZAQC8jBRUiMybA3UD9RuQhbvQEVMVmBrXzJiHxIYr5_SXC_i9faCbjkKARcHvDkrgjXtAzk9Pvrw7Y_MeCixIwUfWNNGVHilqSu9T41QSPCkRK-1inbirnIlBBxe0Q-Z8aaC4FhEwgnEGSstKPCQHXd_Fx4TKYKTTgJCijLWJysQKDIz8e8r4RvuClDuV2jATjOM-F1c2Fxpa2skMFsxgsxksL8ib5ZofE73GtdJv0VKLJFJj5xPgMHZ2GPsvhynIS7SzRfKLDrtrLt12GOz7z5_sMYIVIaXWBXk9C6Ue5gD6mX5WAE0gX9ZK8nAlCSYL6-GdO9k5Ogy2arDM5TDJgrxYhvFK7HjrYr_NMoBkteTqOhnA36VWCm7zaPLQRTdCGKhVVVkQtfLdlfLWI93mW-YX1yXAGq6e_A9tPyW3qvzaNYyrQ3Iw_tzGZwDjRv88v7F_AFYPRYQ priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3Ni9UwEA-6IgiL6Pqx1VWiCB6kbNq0-TjJKrusHjyoCw8vIUmT5wNt1-17-u87k_bVLcI79NJMaTszma9MfiHkFdc2QhbQ5CIKn1fWs9xVgeUqcnAGMYoypG6LT-L8ovq4qBdjwa0f2yq3NjEZ6qbzWCM_LmtMDVihxNvLXzmeGoWrq-MRGjfJLYQuw5YuuZgSLsRSE9uNMkoc92CvJSTPJVwVQnOymTNKmP3_W-ZrrmneNnnND53dI3fHAJKeDBK_T26E9oDsD9U3OmwqOiC3v3WpXP6ANKcTnDftIl3_6WifUJZzCAuXgQJjEY-zp7anbgW08Fa6RgcGCoCVtNyBu8N6Ov1tPa7C93TVUjC7SPjTQmK8sg_Jxdnp1_fn-XiyQu4FZ-u8roMtHALXFM7F2srIWZQ8lMqGKjJbWh288tYri3j6QkPKzQNEDtpqSDhL_ojstV0bDgkVXgurIG4KIlQ6SB1KEDui8kntauUyUmxZbPwIO46nX_wwKf1QwgxiMSAWk8RiWEbeTM9cDqAbO6nfoeQmSgTMTje6q6UZ55-JUdXKFr4snK5E41wTgvBN4LjsykubkZcod4OQGC323Cztpu_Nhy-fzQmGMFwIpTLyeiSKHfwD8GfYwgCcQBStGeXRjBJE5ufDW_Uyo83ozT8Nz8iLaRifxD64NnSbRAPxrRJM7qKBqLxQUsJrHg8aO_GGcw0ZrCwyIme6PGPefKRdfU-o46qAYIfJJ7s__Sm5U6YJVudMHpG99dUmPIOwbe2ep7n5F9NpQNQ priority: 102 providerName: ProQuest |
| Title | Evaluation of two sexual-stage antigens as bivalent transmission-blocking vaccines in rodent malaria |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/33962671 https://www.proquest.com/docview/2528990186 https://www.proquest.com/docview/2524358607 https://www.proquest.com/docview/2551918778 https://pubmed.ncbi.nlm.nih.gov/PMC8103607 https://doaj.org/article/ff858a1c21b946dbbdee6cde3841632a |
| Volume | 14 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1ba9swFBZdy2AvY_e564I2BnsY3mzLluSHMdKR0gVWRrtA2IuQFCkLdHYXJ7v8-52jOKZmJQ8hEB3H6Fx0zqfLJ0JesVJ7QAGzmHtu41zbJDa5S2LpGSQD73nmwm6LM346ycfTYrpHttcdtQpsboR2eJ_UZHn59s_Pvx8g4N-HgJf8XQPjsABQnMEnR8pNgPAHkJkEBurnvFtVQG61cNpIFDwGHF9sD9Hc-B-9RBX4_P8fta-lrf6Wyms56uQeudsWl3S48Yb7ZM9VD8jtb3WYOn9IZqOO2pvWnq5-17QJjMsxlIhzR0HJyM3ZUN1QswBZeAtdYTIDZ8BZtdhA6sO5dfpLW1yRb-iiojAEo-APDZpc6EdkcjL6-vE0bm9ZiC1nySouCqdTgyQ2qTG-0MKzxAvmMqld7hOd6dJZabWVGrn1eQnwmzmoIkpdAvjM2GOyX9WVe0ootyXXEmoox11eOlG6DFwAGfpEaQppIpJuVapsS0GON2FcqgBFJFcbMygwgwpmUElE3nTPXG0IOHZKH6OlOkkkzw4_1Mu5amNReS8LqVObpabM-cyYmXPczhzDJViW6Yi8RDsrpMeocP_NXK-bRn26OFdDLGcY51JG5HUr5GvoA-hnc5wBNIGMWj3Jo54kmMz2m7fupLbur7ICgXACnYzIi64Zn8Q9cZWr10EGal3JE7FLBir0VAoBr3my8dBON4yVgGZFGhHR892e8vot1eJ7YCCXKRQ-iTjc3bNn5E4WAqqIE3FE9lfLtXsOJdzKDMgtMRUDcjAcji_G8H08OvtyPggTIoMQs_8A3vBFhw |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELemTQgkhGB8FQYYBOIBRUvixHYeENqgU8tGhcYmTXsxtmOXSpCMpWXin-Jv5C4fZRFS3_bQl_qitHfnu_ud7Z8Jecky7QEF5AH33AaJtmFgEhcG0jNIBt7z2NW7LSZ8dJx8PElP1sif7iwMbqvsYmIdqPPSYo98O04RGoSR5O_OfgZ4axSurnZXaDRuse9-XwBkq96OP4B9X8Xx3vDo_ShobxUILGfhPEhTpyODpC2RMT7VwrPQC-ZiqV3iQx3rzFlptZUaueR5BnCTOciamc4AbCHRAYT8jYQBlFknG7vDyefDLvYjexvvjuZIvl1BhhAA12P4JEgGGvbSX31LwP-54FIy7G_UvJT59m6TW23JSncaH7tD1lyxSW42_T7aHGPaJNdOy7pBf5fkwyWBOC09nV-UtKp5nQMoRKeOgimRAbSiuqJmBrLwVjrHlAkuh727wECCxQ4-_aUtrvtXdFZQCPQo-EMDFJ_pe-T4SrR-n6wXZeEeEsptxrWESs1xl2ROZC4GR0MeQJGZVJoBiToVK9sSneN9G99VDXgkV41ZFJhF1WZR4YC8WT5z1tB8rJTeRcstJZGiu_6iPJ-qdsYr72UqdWTjyGQJz43JneM2dwwXelmsB-QF2l0hCUeBu3ymelFVavzlUO1g0cQ4l3JAXrdCvoT_APppDk2AJpC3qye51ZMEk9n-cOdeqo1Slfo3pwbk-XIYn8Sdd4UrF7UMVNSSh2KVDOCASAoBr3nQeOxSN4xlgJlFNCCi58s95fVHitm3mudcRlBeheLR6p_-jFwfHX06UAfjyf5jciOuJ1sahGKLrM_PF-4JFI1z87SdqZR8verg8BcDiH8f |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluation+of+two+sexual-stage+antigens+as+bivalent+transmission-blocking+vaccines+in+rodent+malaria&rft.jtitle=Parasites+%26+vectors&rft.au=Yang%2C+Fan&rft.au=Liu%2C+Fei&rft.au=Yu%2C+Xinxin&rft.au=Zheng%2C+Wenqi&rft.date=2021-05-07&rft.pub=BioMed+Central+Ltd&rft.issn=1756-3305&rft.eissn=1756-3305&rft.volume=14&rft.issue=1&rft_id=info:doi/10.1186%2Fs13071-021-04743-0&rft.externalDocID=A661436688 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-3305&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-3305&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-3305&client=summon |